QuickView for 1,4-pregnadiene-2,20-dione-16,17-cyclopentylidenedioxy-9-fluoro-11,21-dihydroxy-21-acetate (compound)

1. Drug target sets for approved compounds
2. L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (3 of 4)
3. L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (2 of 4)
4. L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (1 of 4)

1. Identification and characterization of triamcinolone acetonide, a microglial-activation inhibitor.
2. Exacerbation of allergic contact dermatitis from amcinonide triggered by patch testing.
3. Contact allergy to topical corticosteroids--results from the IVDK and epidemiological risk assessmen…
4. Allergic contact dermatitis to topical drugs--epidemiological risk assessment.
5. Allergic contact dermatitis from amcinonide.

There were no clinical trials for 1,4-pregnadiene-2,20-dione-16,17-cyclopentylidenedioxy-9-fluoro-11,21-dihydroxy-21-acetate